<SEC-DOCUMENT>0001104659-23-004370.txt : 20230117
<SEC-HEADER>0001104659-23-004370.hdr.sgml : 20230117
<ACCEPTANCE-DATETIME>20230117210227
ACCESSION NUMBER:		0001104659-23-004370
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230117
FILED AS OF DATE:		20230117
DATE AS OF CHANGE:		20230117

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Piccina Cintia
		CENTRAL INDEX KEY:			0001907199

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		23532728

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE, MILTON PARK
		STREET 2:		ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			X0 OX14 4R

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm231655-10_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-01-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001621227</issuerCik>
        <issuerName>Adaptimmune Therapeutics PLC</issuerName>
        <issuerTradingSymbol>ADAP]</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001907199</rptOwnerCik>
            <rptOwnerName>Piccina Cintia</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADAPTIMMUNE THERAPEUTICS PLC,</rptOwnerStreet1>
            <rptOwnerStreet2>60 JUBILEE AVENUE, MILTON PARK</rptOwnerStreet2>
            <rptOwnerCity>ABINGDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>OX14 4RX</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Commercial Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Option to purchase Ordinary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.31</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-01-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1407072</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-01-17</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1407072</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1407072</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
        <derivativeTransaction>
            <securityTitle>
                <value>Option to purchase Ordinary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.0012</value>
                <footnoteId id="F3"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-01-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>314256</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F5"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>314256</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>314256</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
        <derivativeTransaction>
            <securityTitle>
                <value>Option to purchase Ordinary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.0012</value>
                <footnoteId id="F6"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-01-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>181560</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2024-01-17</value>
            </exerciseDate>
            <expirationDate>
                <value>2025-03-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>181560</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>181560</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.</footnote>
        <footnote id="F2">Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.</footnote>
        <footnote id="F3">The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.</footnote>
        <footnote id="F4">Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.</footnote>
        <footnote id="F5">The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.</footnote>
        <footnote id="F6">The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Cintia Piccina</signatureName>
        <signatureDate>2023-01-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
